Orbus Pharma Inc. Announces Favorable Results Of Fluvastatin Extended Release Bioequivalence Tests

Orbus Pharma Inc., (TSX:ORB) (“Orbus”) today announced favorable results in its drug development of a once per day formulation for Fluvastatin, a cholesterol reducing drug.